ArticleNature cancer2025
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.
Wen Lei et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
49 papers cite it
this papercites it